View in EDS

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.

Saved in:
Bibliographic Details
Title: Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
Authors: Radovich M; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Solzak JP; Department of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Wang CJ; Department of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Hancock BA; Department of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Badve S; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana., Althouse SK; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Biostatistics and Data Health Science, Indiana University School of Medicine, Indianapolis, Indiana., Bray SM; LifeOmic, LLC, Indianapolis, Indiana., Storniolo AMV; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Ballinger TJ; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Schneider BP; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana., Miller KD; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Aug 02; Vol. 28 (15), pp. 3235-3241.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35551360
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Radovich+M%22">Radovich M</searchLink>; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Solzak+JP%22">Solzak JP</searchLink>; Department of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Wang+CJ%22">Wang CJ</searchLink>; Department of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Hancock+BA%22">Hancock BA</searchLink>; Department of Surgery, Division of Surgical Oncology, Indiana University School of Medicine, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Badve+S%22">Badve S</searchLink>; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Althouse+SK%22">Althouse SK</searchLink>; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Biostatistics and Data Health Science, Indiana University School of Medicine, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Bray+SM%22">Bray SM</searchLink>; LifeOmic, LLC, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Storniolo+AMV%22">Storniolo AMV</searchLink>; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Ballinger+TJ%22">Ballinger TJ</searchLink>; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Schneider+BP%22">Schneider BP</searchLink>; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana.<br /><searchLink fieldCode="AU" term="%22Miller+KD%22">Miller KD</searchLink>; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana.; Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2022 Aug 02; Vol. 28 (15), pp. 3235-3241.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35551360
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-21-3078
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3235
    Titles:
      – TitleFull: Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Radovich M
      – PersonEntity:
          Name:
            NameFull: Solzak JP
      – PersonEntity:
          Name:
            NameFull: Wang CJ
      – PersonEntity:
          Name:
            NameFull: Hancock BA
      – PersonEntity:
          Name:
            NameFull: Badve S
      – PersonEntity:
          Name:
            NameFull: Althouse SK
      – PersonEntity:
          Name:
            NameFull: Bray SM
      – PersonEntity:
          Name:
            NameFull: Storniolo AMV
      – PersonEntity:
          Name:
            NameFull: Ballinger TJ
      – PersonEntity:
          Name:
            NameFull: Schneider BP
      – PersonEntity:
          Name:
            NameFull: Miller KD
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 08
              Text: 2022 Aug 02
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 28
            – Type: issue
              Value: 15
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1